Treatment Buddies Improve Clinic Attendance among Women but Not Men on Antiretroviral Therapy in the Nyanza Region of Kenya
Table 1
Sample characteristics ().
Characteristics
TBy ()
No TBy ()
value
Gender
<0.0001
Male
770 (94.8)
42 (5.2)
Female
1429 (88.3)
189 (11.7)
Age (years; enrollment), median (IQR)
32 (27–39)
30 (25–35)
<0.0001
15–29
852 (88.3)
113 (11.7)
30–44
1038 (90.7)
107 (9.3)
45+
309 (96.6)
11 (3.4)
Education level (enrollment)
0.05
None
57 (98.3)
1 (1.7)
Primary
1118 (91.2)
108 (8.8)
Secondary
665 (89.4)
79 (10.6)
College
164 (93.7)
11 (6.3)
Missing
195 (85.9)
32 (14.1)
Marital status (enrollment)
<0.0001
Single
894 (87.9)
123 (12.1)
Partnered
1076 (93.1)
80 (6.9)
Missing
229 (89.1)
28 (10.9)
Children in household (enrollment)
0.11
0
469 (90.9)
47 (9.1)
1
447 (91.4)
42 (8.6)
2
457 (88.1)
62 (12.0)
3+
563 (92.1)
48 (7.9)
Missing
263 (89.2)
32 (10.9)
Year ART initiated
<0.0001
2007
31 (79.5)
8 (20.5)
2008
242 (80.9)
57 (19.1)
2009
513 (91.3)
49 (8.7)
2010
749 (92.5)
61 (7.5)
2011
664 (92.2)
56 (7.8)
Months from enrollment to ART initiation, median (IQR)
1 (0–3)
1 (0–6)
0.03
<1
964 (91.7)
87 (8.3)
1-2
530 (91.7)
48 (8.3)
2-3
131 (86.2)
21 (13.8)
>3
574 (88.4)
75 (11.6)
CD4 count (cells/mm3; ART initiation), median (IQR)†
180 (82–260)
189 (113–280)
0.52
>350
155 (88.6)
20 (11.4)
200–350
797 (90.2)
87 (9.8)
<200
1207 (91.0)
119 (9.0)
WHO stage (ART initiation)†
0.03
1
526 (88.9)
66 (11.2)
2
697 (88.7)
89 (11.3)
3
809 (92.7)
64 (7.3)
4
156 (92.9)
12 (7.1)
Clinic site
<0.0001
Lumumba
993 (90.8)
101 (9.2)
Tuungane
73 (97.3)
2 (2.7)
PandiPieri
1011 (94.9)
54 (5.1)
FHOK
122 (62.2)
74 (37.8)
Retention during first 6 months on ART
0.001
Missed ≥1 visits
890 (88.2)
119 (11.8)
Missed no visits
1309 (92.1)
112 (7.9)
(%) shown unless otherwise indicated. Significance tests based on nonmissing values. †There were missing data for the following predictors: CD4 count: 45 patients; 40 with treatment buddy and 5 without treatment buddy. WHO stage: 10 patients, all with treatment buddy.
